NEWS | BEAM Alliance


Polyphor announces enrollment of first patient in PRISM-UDR – the second, FDA agreed – Phase III clinical trial for murepavadin in patients with nosocomial pneumonia

Allschwil, Switzerland, April 16, 2019

Polyphor today announced the enrollment of the first patient in its PRISM-UDR clinical trial, the second Phase III study for murepavadin (POL7080) for the treatment of hospital-acquired (HABP) and ventilator-associated bacterial pneumonia (VABP) due to Pseudomonas aeruginosa. Murepavadin is also being evaluated in the ongoing PRISM-MDR Phase III trial in patients with nosocomial pneumonia, which started in March 2018.

Full PR available here